肾病综合征市场（2026—2031）
肾病综合征市场规模预计从2026年的10.5亿美元增长至2031年的17.3亿美元，预测期复合年增长率为10.47%。北美保持最大市场地位，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
肾病综合征市场规模预计从2026年的10.5亿美元增长至2031年的17.3亿美元，预测期复合年增长率为10.47%。北美保持最大市场地位，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 10.47% | 机构预测 |
| 市场规模 | 2026 | USD 1.05 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.73 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_type | primary nephrotic syndrome | 2025 | 58.310% |
| distribution_channel | hospital pharmacies | 2025 | 45.540% |
| end_user | hospitals and clinics | 2025 | 52.140% |
| geography | North America | 2025 | 42.610% |
| modality | treatment | 2025 | 81.240% |
关键结论
- disease_type 维度中，primary nephrotic syndrome 在 2025 年的公开份额为 58.31%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 45.54%。
- end_user 维度中，hospitals and clinics 在 2025 年的公开份额为 52.14%。
- geography 维度中，North America 在 2025 年的公开份额为 42.61%。
- modality 维度中，treatment 在 2025 年的公开份额为 81.24%。
主要参与者
- Pfizer Inc.
- Novartis AG
- F. Hoffmann-La Roche AG
- GSK plc
- Travere Therapeutics, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Diagnosis of Proteinuric Kidney Disease and Nephrotic Syndrome | +2.800% | Global, with concentrated gains in APAC and MEA | Medium term (2-4 years) |
| Expansion of Targeted and Steroid-Sparing Therapies | +2.600% | North America and EU, spilling into Japan and China | Short term (≤ 2 years) |
| Greater Use of Molecular, Serological, and Biomarker-Led Diagnosis | +1.200% | North America and EU, early adoption in South Korea and Australia | Medium term (2-4 years) |
| Increasing Pediatric and Adult Specialty-Nephrology Capacity | +0.900% | APAC core, spillover to MEA | Long term (≥ 4 years) |
| Podocyte-Directed and Non-Immunosuppressive Pipeline Innovation | +1.800% | Global, led by North America | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Treatment Toxicity and Relapse-Driven Treatment Cycling | -0.600% | Global, most pronounced in pediatric populations in APAC and MEA | Short term (≤ 2 years) |
| High Cost and Uneven Reimbursement for Rare-Disease Therapies | -0.800% | North America and EU, with near-total access barriers in South America and MEA | Medium term (2-4 years) |
| Fragmented Phenotyping and Delayed Genetic Diagnosis | -0.400% | MEA, South America, parts of APAC | Long term (≥ 4 years) |
报告关注的关键问题
What is the 2026 size of the nephrotic syndrome market?
The nephrotic syndrome market is valued at USD 1.05 billion in 2026 and is forecast to reach USD 1.73 billion by 2031.
Which disease category is growing fastest?
Secondary nephrotic syndrome is projected to grow at a CAGR of 11.65% during 2026-2031.
Which care setting is expanding fastest for nephrotic syndrome?
Specialty nephrology centers are projected to grow at a CAGR of 11.12% through 2031.
Why are online pharmacies becoming more relevant for nephrotic syndrome care?
Online pharmacies are projected to grow at a CAGR of 12.82% through 2031. Home delivery, e-prescribing, and pharmacy-management systems support access to oral maintenance therapies while allowing continued visibility over refill activity.
Which region is expected to grow fastest?
Asia-Pacific is projected to grow at a CAGR of 12.25% during 2026-2031.
What unmet need remains important in FSGS treatment?
FSGS had no U.S. Food and Drug Administration-approved disease-specific therapy as of 2026. Inaxaplin remains a prominent development candidate for APOL1-mediated kidney disease.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence